Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Karl Erixon"'
Autor:
Ola Fjellström, Sibel Akkaya, Hans-Georg Beisel, Per-Olof Eriksson, Karl Erixon, David Gustafsson, Ulrik Jurva, Daiwu Kang, David Karis, Wolfgang Knecht, Viveca Nerme, Ingemar Nilsson, Thomas Olsson, Alma Redzic, Robert Roth, Jenny Sandmark, Anna Tigerström, Linda Öster
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0113705 (2015)
Activated factor XI (FXIa) inhibitors are anticipated to combine anticoagulant and profibrinolytic effects with a low bleeding risk. This motivated a structure aided fragment based lead generation campaign to create novel FXIa inhibitor leads. A virt
Externí odkaz:
https://doaj.org/article/1a2cc35337574e84979292e3f9e6ec05
Autor:
David Gustafsson, Ingemar Nilsson, Ola Fjellström, Per-Olof Eriksson, Karl Erixon, Wolfgang Knecht, Hans-Georg Beisel, Alma Redzic, Robert G. Roth, Jenny Sandmark, Daiwu Kang, Viveca Nerme, Linda Öster, David Karis, Ulrik Jurva, Tommy Olsson, Sibel Akkaya, Anna Tigerström
Publikováno v:
'PloS One ', vol: 10, pages: e0113705-1-e0113705-42 (2015)
PLoS ONE, Vol 10, Iss 1, p e0113705 (2015)
PLoS ONE
PLoS ONE, Vol 10, Iss 1, p e0113705 (2015)
PLoS ONE
Activated factor XI (FXIa) inhibitors are anticipated to combine anticoagulant and profibrinolytic effects with a low bleeding risk. This motivated a structure aided fragment based lead generation campaign to create novel FXIa inhibitor leads. A virt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5dd4dbe0ba8aa2647b5c7942afe3595
https://epn-library.esrf.fr/flora/jsp/index_view_direct_anonymous.jsp?record=doc:PUB_ESRF:42302
https://epn-library.esrf.fr/flora/jsp/index_view_direct_anonymous.jsp?record=doc:PUB_ESRF:42302